Is MannKind Corporation (MNKD) one of the popular penny stocks on Robinhood to buy?
This article evaluates whether MannKind Corporation (MNKD) is a popular penny stock on Robinhood. It aims to determine if MNKD is a viable investment option for those interested in penny stocks available through the Robinhood platform.
Q4 2025 MannKind Corp Earnings Call Transcript
MannKind Corp (MNKD) reported record quarterly revenue of $112 million in Q4 2025, a 46% increase year-over-year, and completed the acquisition of SC Pharmaceuticals. Despite a GAAP net loss of $15.9 million, the company anticipates a revenue run rate exceeding $450 million in 2026, driven by its diversified product portfolio and advancing clinical programs. The earnings call transcript, dated February 26, 2026, details these financial results and strategic initiatives.
Is MannKind Corporation (MNKD) One of the Popular Penny Stocks on Robinhood to Buy?
MannKind Corporation (MNKD) is highlighted as a popular penny stock on Robinhood, with recent executive presentations detailing the company's evolution and future growth drivers. Key catalysts include a strengthened partnership with United Therapeutics for Tyvaso DPI and the successful acquisition of scPharmaceuticals, expanding MannKind into a new cardiometabolic business unit. The company anticipates significant revenue growth from FUROSCIX, despite analysts suggesting higher peak sales potential.
Vanguard disaggregates holdings; MannKind (MNKD) shows 0 shares in 13G/A
Vanguard Group filed an amended Schedule 13G/A for MannKind Corp (MNKD), reporting 0 shares and 0% beneficial ownership. This change is due to an internal realignment effective January 12, 2026, where certain Vanguard subsidiaries will now report beneficial ownership separately. The filing clarifies that this is a reporting adjustment based on SEC guidance, not a divestment or market trade.
MannKind (MNKD) CFO receives performance-based RSUs and long-term stock options
MannKind Corp's CFO, Christopher B. Prentiss, was granted 221,000 performance-based restricted stock units and 217,000 employee stock options. The performance units vest on January 15, 2029, with payout based on MannKind's total shareholder return compared to the Russell 3000 Pharmaceutical & Biotechnology Index from April 1, 2026, through December 31, 2028. The stock options have an exercise price of $2.44 and a vesting schedule starting March 23, 2027, with full vesting by March 23, 2036.
MannKind (MNKD) CEO receives large PRSU and stock option grants tied to TSR
MannKind CEO Michael Castagna has been granted substantial equity compensation, including 796,000 performance-based restricted stock units (PRSUs) and stock options for 782,000 shares. The PRSUs' vesting, up to 300% of target, is contingent on MannKind's total shareholder return relative to the Russell 3000 Pharmaceutical & Biotechnology Index from April 2026 to December 2028, vesting on January 15, 2029. The stock options, priced at $2.4400, vest partially in March 2027 with the remainder over four years, expiring in March 2036.
MannKind Corporation (NASDAQ:MNKD) Given Average Recommendation of "Moderate Buy" by Brokerages
MannKind Corporation (NASDAQ:MNKD) has received a consensus "Moderate Buy" rating from brokerages, with an average one-year price target of $9.06. The company reported mixed quarterly results, missing EPS estimates but exceeding revenue expectations with a 45.8% year-over-year increase. Insider activity includes CEO Michael Castagna's purchase of 100,000 shares and another insider's sale of 47,006 shares.
MannKind (MNKD) awards performance RSUs and stock options to officer
MannKind Corp (MNKD) has issued new equity awards to its Chief People & Workplace Officer, Stuart A. Tross. These awards include 221,000 performance-based restricted stock units (RSUs) and 217,000 stock options with an exercise price of $2.44. The RSUs vest on January 15, 2029, with payout based on the company's total shareholder return against the Russell 3000 Pharmaceutical & Biotechnology Index, while the stock options vest quarterly over four years after an initial 25% on March 23, 2027.
MannKind (MNKD) CMO receives new RSU and stock option awards
MannKind Corporation's Chief Medical Officer, Ajay Ahuja, has received new equity awards comprising 221,000 performance-based restricted stock units and options for 217,000 shares. The RSUs vest in 2029, with payout linked to MannKind's total shareholder return against the Russell 3000 Pharmaceutical & Biotechnology Index. The stock options have an exercise price of $2.44, vest over time starting in 2027, and expire in 2036, all reflecting compensation awards.
MannKind (MNKD) EVP receives new performance RSU and option awards
MannKind Corporation's EVP and General Counsel, David Thomson, was awarded 221,000 performance-based restricted stock units (RSUs) and options for 217,000 shares. The RSUs vest on January 15, 2029, with payout dependent on the company's total shareholder return compared to the Russell 3000 Pharmaceutical & Biotechnology Index. The stock options have an exercise price of $2.44 per share and will vest incrementally starting March 23, 2027.
MannKind's Furoscix Autoinjector under FDA review for expanded label
MannKind Corporation (MNKD) has submitted a supplemental New Drug Application (sNDA) to the FDA for its Furoscix autoinjector. The sNDA seeks to expand the label to include treatment for acute decompensated heart failure (ADHF) in patients with persistent congestion despite receiving oral diuretics, aiming to reduce ADHF-related hospitalizations. This move could significantly broaden Furoscix's addressable market and impact the company's financial outlook.
MannKind Corp stock hits new 52-week low on NASDAQ amid analyst downgrades and earnings miss
MannKind Corp (MNKD) shares fell to a new 52-week low of $2.52 on NASDAQ following analyst downgrades and a disappointing earnings report. Despite beating revenue estimates, an EPS miss and ongoing cost pressures have raised investor concerns. However, strong institutional ownership and recent insider buying by the CEO suggest potential for a rebound.
MannKind (Nasdaq:MNKD) - Stock Analysis
This Simply Wall St stock analysis provides an overview of MannKind Corporation (NASDAQ:MNKD), a biopharmaceutical company specializing in chronic disease care. It details the company's current valuation, future growth prospects, past performance, and financial health, noting that the stock is trading at a significant discount to its estimated fair value. The report also highlights positive analyst sentiment regarding revenue growth and pipeline advancements, alongside financial risks such as negative shareholder equity.
MannKind Corp. Stock Plummets to New 52-Week Low of $3.29
MannKind Corp. (MNKD) shares have plummeted to a new 52-week low of $3.29, significantly underperforming the S&P 500 with a one-year decline of 22.05%. Despite a reported 36.97% growth in operating profit over the last five years, the company faces challenges including a negative return on equity, a high debt-to-equity ratio, and weak debt servicing ability. These financial metrics suggest weak long-term fundamental strength, contributing to its risky market position.
MannKind Corp. Hits Day Low of $3.29 Amid Price Pressure
MannKind Corp. (MNKD) experienced significant stock volatility, hitting an intraday low of $3.29 and showing substantial declines over various periods, underperforming the S&P 500. Financial analysis points to challenges including a negative book value, issues with debt servicing (poor EBIT to interest ratio), and a negative return on equity, raising concerns about its overall financial health and market position. The company operates in the Pharmaceuticals & Biotechnology sector and is classified as a small-cap player.
(MNKD.O) | Stock Price & Latest News
This article provides detailed financial information and company data for MannKind Corporation (MNKD.O), a biopharmaceutical company focusing on cardiometabolic and orphan lung diseases. It includes recent news relevant to the company, such as United Therapeutics' late-stage drug win and past FDA decisions impacting MannKind's therapies, alongside comprehensive reports on financial performance, executive leadership, and sustainability. The data presented covers income statements, balance sheets, and cash flow for recent years.
MannKind Corp Stock (ISIN: US5638651064) Faces Pressure Amid Biotech Selloff and Analyst Cuts
MannKind Corp (NASDAQ: MNKD) stock is facing pressure due to a broader biotech sector selloff and recent analyst target cuts, despite positive insider buying activity and strong financial performance. The company, known for its inhaled therapies Afrezza and Tyvaso DPI, reported significant revenue growth, but faces competitive risks and market volatility. European investors are considering its growth potential in inhalation therapeutics amidst diabetes prevalence and potential M&A interest.
Avoro Capital Advisors LLC Lowers Position in MannKind Corporation $MNKD
Avoro Capital Advisors LLC significantly reduced its stake in MannKind Corporation (NASDAQ:MNKD) by 23.6% in the third quarter, selling over 1.3 million shares. This move places MannKind as the 26th largest position in Avoro's portfolio, valued at approximately $24 million. Despite varied analyst ratings, the consensus remains a "Moderate Buy" with an average price target of $9.06, even as some firms like RBC and Wedbush have trimmed their targets.
MannKind (NASDAQ: MNKD) CEO purchases 100,000 shares in market trade
MannKind Corp CEO Michael Castagna purchased 100,000 shares of common stock in an open-market transaction at a weighted average price of $2.59 per share on March 10, 2026. Following this purchase, he directly owns 2,575,911 shares, with an additional 1,500 shares held indirectly through his spouse. This transaction was reported in a Form 4 SEC filing, indicating a positive sentiment for the company.
Why MannKind Needs Your Attention
MannKind Corporation (MNKD) is poised for significant developments with upcoming presentations on Afrezza clinical data, an FDA decision for pediatric Afrezza, and an FDA decision for the Furoscix ReadyFlow Autoinjector. The company reported strong revenue growth in 2025, driven by Afrezza sales, royalties, and collaboration revenue, and is advancing its pipeline with MNKD-201 for idiopathic pulmonary fibrosis. With a solid cash position and multiple near-term catalysts, MannKind warrants investor attention.
MNKD: Portfolio diversification and product launches are set to drive accelerated growth and value
MannKind Corporation (MNKD) is pursuing a strategy focused on diversifying its portfolio, accelerating growth, and launching key products like FUROSCIX and Afrezza. The company is shifting revenue streams toward direct control and is making significant investments in commercialization and R&D to enhance future value. This information is based on insights from the Leerink Global Healthcare Conference 2026 Audio Transcript.
MannKind (NASDAQ:MNKD) CEO Buys $259,000.00 in Stock
MannKind CEO Michael Castagna purchased 100,000 shares of MNKD stock for $259,000 on March 10th, increasing his total holdings to 2,575,911 shares. This significant buy follows earlier sales in December at a higher price, indicating a repurchase at a much lower valuation. The stock trades around $2.61, and analysts currently rate it as a "Moderate Buy" with a consensus price target of $9.06.
MannKind (NASDAQ:MNKD) Hits New 12-Month Low - Here's Why
MannKind (NASDAQ:MNKD) hit a new 52-week low of $2.52 on high volume, despite beating revenue expectations with a 45.8% year-over-year increase, though it missed EPS estimates. Analysts have maintained a "Moderate Buy" consensus rating with an average price target of $9.06, even after some price target reductions. Insider selling and institutional investment activity were also noted.
Afrezza needle-free insulin for kids heads for FDA decision May 29, 2026
MannKind (NASDAQ: MNKD) will present new clinical and real-world data for Afrezza inhaled insulin at ATTD 2026, including on pediatric dosing from the INHALE-1 study. A supplemental Biologics License Application (sBLA) for Afrezza in children aged 4–17 has a PDUFA target action date of May 29, 2026. If approved, Afrezza would be the first needle-free insulin option for pediatric patients in over a century.
MannKind Announces Settlement of Convertible Senior Notes
MannKind Corporation announced it has settled the remaining $36.3 million aggregate principal amount of its 2.50% convertible senior notes, which were tendered for conversion before the March 1, 2026 maturity date. The settlement, completed on March 4, 2026, involved a payment of $35.5 million in cash and 569,023 shares of MannKind common stock. MannKind is a biopharmaceutical company focused on transforming chronic disease care through patient-centric solutions for cardiometabolic and orphan lung diseases.
Vanguard Group Inc. Has $94.68 Million Holdings in MannKind Corporation $MNKD
Vanguard Group Inc. reduced its stake in MannKind Corporation (NASDAQ:MNKD) by 2.9% in the third quarter, now holding 17.63 million shares valued at $94.68 million, representing 5.75% ownership. This comes amid mixed financial results for MannKind, with revenue beating estimates but EPS missing, and analysts have adjusted price targets though the consensus remains a "Moderate Buy." Insider selling has also been reported, while institutional investors collectively own nearly half of the company's stock.
MannKind Announces Settlement of Convertible Senior Notes
MannKind Corporation announced it has settled the remaining $36.3 million aggregate principal amount of its 2.50% convertible senior notes. The settlement, which occurred on March 4, 2026, involved $35.5 million in cash and 569,023 shares of MannKind common stock. The biopharmaceutical company focuses on innovative solutions for cardiometabolic and orphan lung diseases.
MannKind settles $36.3M convertible notes with cash, shares
MannKind Corporation settled its remaining $36.3 million aggregate principal amount of 2.50% convertible senior notes with $35.5 million in cash and 569,023 shares of common stock. The settlement occurred as the company's shares traded near their 52-week low. Despite recent stock weakness and an EPS shortfall, some analysts suggest the stock is undervalued, while others have downgraded it due to uncertainties surrounding product royalties and approvals.
MannKind Corp (MNKD) Q4 2025 Earnings Call Highlights: Record Revenue and Strategic Acquisitions Propel Growth
MannKind Corp (MNKD) reported record Q4 2025 revenue of $112 million, a 46% increase year-over-year, and completed the acquisition of SC Pharmaceuticals. Despite a GAAP net loss, the company anticipates over $450 million in revenue for 2026, driven by strategic investments, product launches like the Afrezza pediatric approval and Furoix auto-injector, and the advancement of its MNKD 201 idiopathic pulmonary fibrosis program with blockbuster potential. Challenges include potential variability in Tyvaso DPI sales, competitive pressures in the PAH market, and the financial strain of heavy investment in pipeline and infrastructure.
MannKind Announces Settlement of Convertible Senior Notes
MannKind Corporation (Nasdaq: MNKD) announced the settlement of the remaining $36.3 million aggregate principal amount of its 2.50% convertible senior notes that were tendered for conversion. The settlement, which occurred on March 4, 2026, involved $35.5 million in cash and 569,023 shares of MannKind common stock. The company focuses on developing and commercializing treatments for cardiometabolic and orphan lung diseases.
MannKind closes note deal with $35.5M cash and 569,023 shares
MannKind Corporation announced it has settled the remaining $36.3 million aggregate principal amount of its 2.50% convertible senior notes through a combination of $35.5 million in cash and the issuance of 569,023 shares of common stock. This settlement occurred on March 4, 2026, ahead of the notes' March 1, 2026, maturity date. The company anticipates this move will remove debt from its balance sheet while causing modest shareholder dilution.
MannKind Announces Settlement of Convertible Senior Notes
MannKind Corporation announced the settlement of the remaining $36.3 million aggregate principal amount of 2.50% convertible senior notes. The settlement occurred on March 4, 2026, and involved $35.5 million in cash and 569,023 shares of MannKind common stock. The biopharmaceutical company focuses on cardiometabolic and orphan lung diseases, aiming to provide patient-centric solutions.
MannKind (NASDAQ:MNKD) Price Target Lowered to $8.00 at Wedbush
Wedbush has lowered its price target for MannKind (NASDAQ:MNKD) to $8.00 from $10.00, while maintaining an "outperform" rating, implying a significant upside. The biopharmaceutical company recently reported Q4 EPS of -$0.05, missing estimates, but revenue of $111.96 million surpassed expectations, growing 45.8% year-over-year. Analyst sentiment for MannKind is mixed, with an average rating of "Moderate Buy" and an average target price of $9.06, while insider selling and institutional ownership changes have also been noted.
MannKind to Participate in Upcoming Investor Conferences
MannKind Corporation (Nasdaq: MNKD) announced its participation in two upcoming investor conferences in Miami: the Leerink Partners 2026 Global Healthcare Conference on March 10 and the Barclays 28th Annual Global Healthcare Conference on March 11. Michael Castagna, PharmD, CEO, and Chris Prentiss, CFO, will represent MannKind, a biopharmaceutical company focused on chronic disease care, at these events through fireside chats and one-on-one meetings. Webcasts of the sessions will be available on the company's investor relations website for about 90 days.
MannKind Corporation (MNKD) Outlines Expansion Plans and Revenue Targets
MannKind Corporation announced ambitious expansion plans and revenue targets at the Oppenheimer healthcare conference, projecting over $450 million in revenue by 2026. Key drivers include Afrezza for children, the FUROSCIX autoinjector, and the new MNKD-201 lung disease program. The company also reported strong Q4 2025 financial results, with revenues up 46% to $112 million, and expects significant cash flow from Tyvaso royalties.
MannKind CEO and CFO to speak at two Miami healthcare events
MannKind Corporation (Nasdaq: MNKD) announced that its CEO, Michael Castagna, and CFO, Chris Prentiss, will participate in two upcoming investor conferences in Miami on March 10-11, 2026. They will engage in fireside chats and one-on-one meetings with investors at the Leerink Partners Global Healthcare Conference and the Barclays Global Healthcare Conference. Live audio webcasts and recorded sessions will be available on the company's investor relations website for approximately 90 days.
MannKind (MNKD) director adds 12,000 shares via Market Price Stock Purchase Plan
MannKind Corp director Shannon James Samuel acquired 12,000 shares of common stock at $3.27 per share through the company's Market Price Stock Purchase Plan, which was approved by the Board of Directors on March 1, 2026. This transaction increased Samuel's direct holdings to 64,635 shares in MannKind. The acquisition is noted as participation in a board-approved plan rather than an open-market trade.
[Form 4] MANNKIND CORP Insider Trading Activity
David Thomson, an executive at MannKind Corp (MNKD), reported insider trading activity via a Form 4 filing. The filing indicates the partial vesting of employee stock options granted in 2016 and 2017 after specific performance milestones were achieved on February 26, 2026. This activity involves 20,000 options at an exercise price of $4.55 and 37,525 options at an exercise price of $1.42.
MannKind (NASDAQ:MNKD) Stock Price Down 6.6% After Analyst Downgrade
MannKind (NASDAQ:MNKD) stock fell 6.6% after Wall Street Zen downgraded it from buy to hold, with shares trading as low as $3.03. The company missed EPS expectations but exceeded revenue estimates for the last quarter. Insider selling has also been noted, with 262,846 shares sold in the last 90 days.
MannKind (MNKD) HR chief adds stock and performance-based options
MannKind Corp's Chief People & Workplace Officer, Stuart A. Tross, acquired 15,290 shares of common stock at $3.27 per share through the company's Market Price Stock Purchase Plan, increasing his direct holdings to 1,000,297 shares. Additionally, he gained stock options for 20,000 and 28,143 shares after performance milestones from 2017 grants were met on February 26, 2026, leading to partial vesting of those awards. These transactions were reported in a recent SEC Form 4 filing.
MannKind Corporation (NASDAQ:MNKD) Given Average Recommendation of "Moderate Buy" by Analysts
Nine analysts have given MannKind Corporation an average "Moderate Buy" rating with a target price of $9.21. The company's recent mixed quarterly results, including a revenue beat but EPS miss, led to stock volatility and a 52-week low, despite institutional investors increasing their positions. Insider selling, including by the CEO, and a sector-wide biotech downturn also contributed to negative sentiment.
MannKind Corporation (MNKD): A Bull Case Theory
This article summarizes a bullish thesis on MannKind Corporation (MNKD), highlighting its growth drivers including the inhalable insulin Afrezza, its potential pediatric label expansion, and diversification through acquisitions. The company's strategic partnerships and innovation focus position it for revenue expansion, despite the inherent volatility of biopharma stocks. The article suggests MannKind presents an attractive risk/reward profile for investors looking for growth.
MannKind Corporation (MNKD): A Bull Case Theory
This article summarizes a bullish thesis on MannKind Corporation (MNKD), highlighting its lead product Afrezza, an inhalable insulin, and its potential label expansion for pediatric patients. The company also benefits from its manufacturing of Tyvaso DPI and recent acquisitions diversifying its pipeline, positioning it for significant growth and investor interest. Despite inherent biopharma volatility, these factors present an attractive risk/reward profile for investors.
MNKD: RBC Capital Downgrades MannKind with Price Target Cut by 5
RBC Capital has downgraded MannKind (MNKD) from "Outperform" to "Sector Perform" and significantly cut its price target from $7.50 to $3.50, reflecting a 53.33% decrease. This adjustment suggests a less optimistic outlook on MannKind's market position and future growth. Despite the downgrade, other analysts have recently reiterated "Buy" ratings with higher price targets, and the average target price from 9 analysts implies an 186.58% upside from the current price.
What's Going On With MannKind Stock Friday?
MannKind Corporation reported its Q4 and full-year 2025 financial results, with adjusted EPS in line with expectations and sales exceeding Street views. The company's revenues saw an increase due to royalties, collaborations, and product sales, driven by the addition of Furoscix and continued growth in Afrezza and UT-related revenues. Despite a bearish short-to-medium term technical outlook, analysts maintain a "Buy" rating with an average price target of $8.38, though HC Wainwright & Co. recently lowered its target to $8.00.
MannKind Corp reports results for the quarter ended December 31 - Earnings Summary
MannKind Corp has reported its earnings results for the quarter that ended on December 31. The report contains a summary of the company's financial performance. This brief article was provided by Refinitiv.
MannKind hits 52-week low after Q4 earnings miss
MannKind (MNKD) shares reached a new 52-week low after reporting Q4 2025 earnings that missed Street forecasts, following a significant slump in the previous session. Despite a 46% year-over-year topline growth, the company's financial performance disappointed investors. This led to a continued decline in stock value.
MannKind Corp (NASDAQ:MNKD) Reports Q4 2025 Revenue Beat and Strategic Outlook for 2026
MannKind Corporation reported strong Q4 2025 revenues of $112.0 million, surpassing analyst expectations due to the acquisition of scPharmaceuticals and growth in Afrezza sales, though it posted a net loss. The company is strategically focused on integrating its new cardiometabolic franchise and expanding Afrezza, with key FDA decisions expected in 2026. Despite the EPS miss, the market reacted positively to the revenue beat and the promising outlook for integration and pipeline advancements.
Earnings Flash (MNKD) MannKind Corporation Reports Q4 Revenue $112.0M, vs. FactSet Est of $97.6M
MannKind Corporation (MNKD) announced its fourth-quarter revenue reached $112.0 million, significantly exceeding FactSet's estimate of $97.6 million. This release highlights the company's financial performance for the final quarter of 2025. The stock saw a decline after its Q4 adjusted earnings fell, despite the revenue increase.
MannKind: Fourth Quarter Earnings Overview
MannKind Corp. reported a net loss of $15.9 million, or 5 cents per share, for the fourth quarter, missing analyst expectations of a 1 cent per share loss. Despite the net loss, the company's revenue for the quarter reached $112 million, surpassing the consensus estimate of $96.8 million. For the full year, MannKind achieved a net income of $5.9 million and total revenue of $349 million.
